ThreatMetrix Exceeds 45% Annual Growth as Organizations Embrace Digital Identity as Must-Have Technology
ThreatMetrix ®, The Digital Identity Company®, today announced 45 percent growth in billings year-on-year, as implementing digital identity solutions became a key priority for organizations in 2017.
In the past quarter, average daily transaction volume processed by ThreatMetrix surged from 75 million to more than 100 million transactions, contributing rich data to the world’s only digital identity graph. Throughout 2017, nearly 150 new companies per quarter were added to the Digital Identity Network®, giving ThreatMetrix customers an unparalleled global view into true digital identity and user trust.
“Organizations of all shapes and sizes are embracing ThreatMetrix ID™ to recognize true customers, operate digital businesses securely and profitably, and improve the user experience – all without compromising privacy,” says Frank Teruel, chief finance officer at ThreatMetrix. “Every quarter, the demand from customers is exceeding expectations. We have invested significant energy and capital into advancing our digital identity mission, and we are enjoying seeing the fruits of that labor.”
Global financial services now account for more than half of ThreatMetrix worldwide billings, and led to an expanding presence in major financial hubs. ThreatMetrix has a new location in the iconic Empire State Building in New York as well as new offices in Toronto, Singapore and Munich.
ThreatMetrix offers digital businesses across the globe the ability to instantaneously differentiate between trusted users and cybercriminals. Compared to legacy approaches relying on simple device recognition, digital identity intelligence is 2.6 times more effective at customer recognition for financial services organizations.1
The demand for digital identity solutions spans various industries – from traditional brick-and-mortar banks and big-box retail merchants, to digital-born organizations in the fintech, insurance, media, and gaming space.
“There has never been a more exciting time to be in our space, as ThreatMetrix re-writes the rules of what is possible in digital identity,” adds Teruel. “There is a bright future ahead and it’s exciting to shape the path ThreatMetrix will pursue in the coming quarters and years.”
Executives from major corporations, including Standard Chartered Bank, Uber, Visa, Pitney Bowes, Netflix, JP Morgan Chase, Ctrip, TD Bank, and Citibank, presented on the main stage at the Digital Identity Summit 2017, hosted by ThreatMetrix. These companies are emerging as thought leaders in the area of digital identity and are helping drive industry-wide investment in this innovative technology.
Mobile transactions, which surpassed 50 percent of traffic for the first time on the ThreatMetrix Digital Identity Network, are also helping create demand as digital businesses look to secure this increasingly popular consumer channel. Mobile provides customers an easy and convenient way to carry out an array of daily activities and transactions. This is particularly pronounced in banking, with more than 60 percent of financial services transactions taking place on mobile devices.
ThreatMetrix has received notable industry recognition, including being named the sole Leader in the 2017 Forrester Wave™: Risk Based Authentication. Other industry recognition in 2017 came from Javelin Strategy and Research, which named ThreatMetrix as leader in multiple categories in the Identity Proofing and Platform Scorecard.
The impressive list of global companies working with ThreatMetrix continues to expand and includes: Airbnb, Alipay, Banco Sabadell, Banque Casino, BPCE, Commercial Bank of Dubai, Gumtree, Homeaway, Lloyds Banking Group, MecardoLibre, Moneycorp, Netflix, Scotiabank and Yandex.Money.
About ThreatMetrix
ThreatMetrix®, The Digital Identity Company®, empowers the global economy to grow profitably and securely without compromise. With deep insight into 1.4 billion anonymized user identities, ThreatMetrix ID™ delivers the intelligence behind 75 million daily authentication and trust decisions to differentiate legitimate customers from fraudsters in real time.
1 ThreatMetrix Q3 2017 Cybercrime Report
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171218005455/en/
Contact information
Media Contacts
Lizzie Clitheroe
ThreatMetrix
Tel:
+1 408 200 5755
lclitheroe@threatmetrix.com
or
Jenny
Overell
Finn Partners
Tel: +1 925 878 5655
Jenny.Overell@finnpartners.com
About Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists23.4.2024 13:00:00 CEST | Press release
Incyte (Nasdaq:INCY) and Escient Pharmaceuticals, a clinical-stage drug discovery and development company advancing novel small molecule therapeutics for systemic immune and neuro-immune disorders, have entered into a definitive agreement under which Incyte has agreed to acquire Escient, including EP262, a first-in-class, potent, highly selective, once-daily small molecule antagonist of Mas-related G protein-coupled receptor X2 (MRGPRX2) and EP547, a first-in-class oral MRGPRX4 antagonist. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240423725958/en/ “As a company dedicated to innovation and the discovery of transformative medicines, we are excited to add EP262 and EP547 to our portfolio. This acquisition builds on our strategy to develop differentiated and first-in-class medicines with high potential,” said Hervé Hoppenot, Chief Executive Officer, Incyte. “EP262 and EP547 are complementary additions to our portfolio, prov
REPLY S.p.A.: Shareholders’ Meeting Approves the 2023 Financial Statements23.4.2024 12:43:00 CEST | Press release
The General Shareholders’ meeting of Reply S.p.A. [EXM, STAR: REY] today approved the Financial Statements for the financial year 2023, confirming the distribution of a gross dividend of €1.00 per share. The dividend will be paid on 22 May 2024, with dividend date set on 20 May 2024 (record date on 21 May 2024). 2023 Financial Statement The Reply Group closed the 2023 financial year with a consolidated turnover of €2,118.0 million, recording a 12.0% increase compared to €1,891.1 million in 2022. Consolidated EBITDA was €325.1 million, up 3.5% compared to €340.3 million recorded in 2022 (growth yoy is 20% net of the release of COVID funds accounted in 2022). EBIT, from January to December, was €292.7 million, up 2.5% compared to €285.5 million recorded in 2022 (growth yoy is 22.7% net of the release of COVID funds accounted in 2022). The Group net profit was at €186.7 million. In 2022, the corresponding figure was €191.0 million. The Shareholders’ Meeting also adopted the following reso
Eaton’s Mobility Group Chosen to Supply Electromechanical Variable Valve Actuation Technology to Great Wall Motor23.4.2024 12:30:00 CEST | Press release
Intelligent power management company Eaton today announced it has been chosen to supply an electromechanical actuation system (EMAS) that can deliver an early intake valve closing (EIVC) to the China-based automaker Great Wall for use in a line of hybrid-electric vehicles (HEV). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240423118914/en/ Eaton’s electromechanical actuation system (EMAS) can be easily integrated into a valvetrain and the cylinder head space and controlled by a simple electric actuator. (Photo: Business Wire) “Emissions regulations are driving the adoption of new technologies by our global customers,” said Alessio Lorenzon, global engineering manager, Valves, Eaton’s Mobility Group. “We’re proud to supply Great Wall with our variable valve actuation technology which, in combination with vehicle hybridization, will improve fuel economy in their newest hybrid passenger vehicle lineup.” The Eaton EMAS is a di
Rasa Recognized as a Representative Vendor in Gartner ® Market Guide for Conversational AI Solutions23.4.2024 12:03:00 CEST | Press release
Rasa, a leader in generative conversational AI, proudly announces its recognition as a Representative Vendor in the Gartner® Market Guide for Conversational AI Solutions. Rasa believes this acknowledgment highlights its pivotal role in the future of AI-driven communication and its commitment to delivering innovative solutions that enhance business interactions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240423570629/en/ Rasa has been recognized as a Representative Vendor in the Gartner Market Guide for Conversational AI Solutions, highlighting its role in transforming business operations through AI-driven conversations. This acknowledgment underscores the importance of evaluating the Conversational AI market to enhance customer interactions, achieve cost efficiencies, and elevate customer service. (Graphic: Business Wire) Melissa Gordon, CEO of Rasa, shares her thoughts: “We think recognition from Gartner® validates our
BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer23.4.2024 12:00:00 CEST | Press release
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the European Commission (EC) has approved tislelizumab as a treatment for non-small cell lung cancer (NSCLC) across three indications, including first- and second-line use. “Tislelizumab is foundational for BeiGene’s solid tumor portfolio and has demonstrated its potential across multiple tumor types, including NSCLC, in which there remains a significant unmet need at all stages of the disease,” said Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeiGene. “Today’s EC authorization marks the second in the region for tislelizumab, with both NSCLC and locally advanced or metastatic esophageal squamous cell carcinoma now approved in the European Union. Second-line use in ESCC was also approved just weeks ago by the U.S. Food and Drug Administration, putting us well on our way to fulfilling our commitment to bring this innovative therapy to many more patients around the